Valproic acid
- Generic Name
- Valproic acid
- Brand Names
- Depakene, Depakote, Epival
- Drug Type
- Small Molecule
- Chemical Formula
- C8H16O2
- CAS Number
- 99-66-1
- Unique Ingredient Identifier
- 614OI1Z5WI
- Background
Valproic acid, or valproate, is an fatty acid derivative and anticonvulsant originally synthesized in 1881 by Beverly S. Burton. It enjoyed use as a popular organic solvent in industry and pharmaceutical manufacturing for nearly a century. In 1963, a serendipitous discovery was made by George Carraz during his investigations into the anticonvulsant effects o...
- Indication
Indicated for:
1) Use as monotherapy or adjunctive therapy in the management of complex partial seizures and simple or complex absence seizures.
2) Adjunctive therapy in the management of multiple seizure types that include absence seizures.
3) Prophylaxis of migraine headaches.
4) Acute management of mania associated with bipolar disorder.
...
- Associated Conditions
- Bipolar Disorder (BD), Complex Partial Seizure Disorder, Depressive Episodes, Migraine, Petit Mal Epilepsy, Seizure, multiple types, Acute Manic episode
- Associated Therapies
- -
Scientists map use of epilepsy drug in England and Wales linked to birth defects
Scientists mapped sodium valproate use in England and Wales, revealing dispensing patterns vary, with higher rates in the north-west and coastal east, highlighting potential inequalities. The study, backed by Health Data Research UK, combined national datasets to understand medicine use, demonstrating the power of data-driven research.
Long-Term Data On Olanzapine and Samidorphan Highlight Maintained Schizophrenia
OLZ/SAM (Lybalvi) maintained symptom control over 4 years in patients with schizophrenia, schizophreniform disorder, or bipolar I disorder, with lower weight gain and fewer AEs compared to olanzapine alone.
Intra-Cellular Therapies Submits Supplemental New Drug
Intra-Cellular Therapies submits sNDA to FDA for CAPLYTA as adjunctive therapy for MDD, based on positive results from Studies 501 and 502, showing robust efficacy and favorable safety profile. CAPLYTA, if approved, would treat over 30 million adult patients in the US for three major psychiatry indications.
Intra-Cellular Therapies Submits Supplemental New Drug Application (sNDA) to FDA for ...
Intra-Cellular Therapies submits sNDA to FDA for CAPLYTA as adjunctive therapy for MDD, based on positive results from Studies 501 and 502, showing robust efficacy and favorable safety profile.
Newer antiseizure drugs safe for pregnancy, Stanford Medicine-led study shows
Pregnancy challenges for women with epilepsy include medication risks like valproate's link to autism and lower IQ, and the need for dose adjustments due to faster metabolism. A study followed 298 children of women with epilepsy to age 6, finding no difference in verbal abilities compared to healthy women's children, though medication levels in the third trimester had nuanced effects. Folate supplementation was beneficial, while acetaminophen showed risks. Further research is needed to understand the long-term effects of various epilepsy drugs and genetic factors influencing outcomes.
Newer Epilepsy Meds Safe During Pregnancy, Won't Affect Kids' Neurodevelopment
Newer anti-seizure meds, like lamotrigine and levetiracetam, pose no risk to fetal neurodevelopment, according to a study tracking 387 children up to age 6. No differences in language scores were found between children exposed to these drugs in utero and those who were not.
Newer Epilepsy Medications Used During Pregnancy Do Not Affect Neurological Development in Children
Children of mothers who took newer antiseizure medications during pregnancy showed no worse neurodevelopmental outcomes at age 6, according to a long-term NIH-funded study published in JAMA Neurology. The study found no differences in language scores between children exposed to the medications and those who were not, with most mothers taking lamotrigine, levetiracetam, or a combination. High doses of folate during pregnancy were associated with better cognitive and behavioral outcomes.
Related Clinical Trials:
Lumateperone Demonstrates Positive Efficacy for Schizophrenia Relapse Prevention
Lumateperone (Caplyta) showed significant efficacy in preventing relapse in schizophrenia patients in Study 304, with a 63% reduction in relapse risk compared to placebo. The treatment was well-tolerated, with headache being the most common adverse event.
Lumateperone Demonstrates Efficacy in Reducing Symptomatic Relapse Risk in Schizophrenia
Intra-Cellular Therapies reports positive results from a study on 42 mg lumateperone (Caplyta) for relapse prevention in schizophrenia. The study showed significant reduction in relapse risk (HR, 0.37; 95% CI, 0.22-0.65) and better safety compared to placebo. Lumateperone is FDA-approved for schizophrenia and bipolar depression.
CAPLYTA Shows Breakthrough 63% Reduction in Schizophrenia Relapse Risk
Intra-Cellular Therapies announced positive Phase 3 results for CAPLYTA (lumateperone) in preventing schizophrenia relapse, showing a 63% reduction in relapse risk vs. placebo (p=0.0002), with 16.4% of lumateperone patients relapsing vs. 38.6% in the placebo group. The drug was generally well-tolerated, with headache as the most common adverse event.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath